Cart

YOUR CART IS EMPTY

Add research compounds to begin your order.

Peer-reviewed human trials and related publicationsSee approved evidence mapCompleted

New England Journal of Medicine

RET-STUDY-P004

Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine. 2023. DOI: 10.1056/NEJMoa2301972. PMID: 37366315. NCT04881760. https://doi.org/10.1056/NEJMoa2301972

Study design

Record details

Design: Peer-reviewed human trials and related publications

Evidence record

Endpoints, findings, and limitations

Limitations

This study record is an evidence-index entry. Interpret the design, material, population or model, endpoints, findings, and limitations only within the linked approved source and compound evidence map; do not transfer outcomes across compounds, materials, cohorts, or models.

Reports and sources

Reference ledger

P004Peer-reviewed human trials and related publications

New England Journal of Medicine

Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. Jastreboff AM, et al. Triple-hormone-receptor agonist retatrutide for obesity. New England Journal of Medicine. 2023. DOI: 10.1056/NEJMoa2301972. PMID: 37366315. NCT04881760. https://doi.org/10.1056/NEJMoa2301972(2023). DOI: 10.1056/NEJMoa2301972